Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Impressive Growth | Boston Scientific reports robust 18% organic sales growth, outperforming market expectations and raising 2024 guidance to 15% organic growth |
Watchman's Potential | Explore how Watchman FLX device's clinical success could expand addressable market by millions, driving significant growth through the decade |
Market Leadership | Delve into Boston Scientific's position as a top-performing large-cap MedTech company, with analysts anticipating meaningful margin expansion |
Analyst Outlook | Average price target of $89, ranging from $78 to $98, reflects confidence in BSX's innovative pipeline and market expansion strategies |
Metrics to compare | BSX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBSXPeersSector | |
---|---|---|---|---|
P/E Ratio | 74.4x | −6.3x | −0.7x | |
PEG Ratio | 1.58 | 0.20 | 0.00 | |
Price/Book | 6.4x | 4.4x | 2.6x | |
Price / LTM Sales | 8.4x | 4.4x | 3.2x | |
Upside (Analyst Target) | 8.4% | 13.9% | 43.2% | |
Fair Value Upside | Unlock | −10.2% | 6.8% | Unlock |